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1991.--The present study was undertaken to assess ff hypothalamic 13-endorphin (13E) and/or brain mu opioid receptors are associ- 
ated with 2, 3, 7, 8-tenachiorodibenzo-p-dioxin (TCDD) (50 p.g/kg)-induced hypophagia and body weight decline in rats. Hypo- 
thaiamic IBE concentrations were initially increased to 166% of controls on day 1, and then were depressed to 39% and 49% of 
control values on days 2 and 3, respectively. Brain rnu opioid receptor number was increased 60% in TCDD-treated rats at day 3 
without a change in the binding affinity. Food-restricted rats did not exhibit changes in hypothaiamic IBE concentrations or brain 
mu opioid receptor number. These results indicate that TCDD causes early perturbations in hypothaiamic IBE concentrations and 
brain mu receptor number, which may contribute to the mechanisms by which TCDD leads to decreased food intake and progres- 
sive weight loss. 
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TCDD is an undesired by-product produced during the synthesis 
of various chlorinated phenolic compounds, incineration of waste, 
and bleaching of paper pulp. There is considerable concern of 
potential health hazards associated with the release of this sub- 
stance into the environment. Animals exposed to a single, oral 
dose of TCDD typically begin to exhibit reduced food intake af- 
ter two to three days that is associated with progressive weight 
loss, and mobilization of adipose tissue stores (5, 7, 9). Further- 
more, loss of appetite and decreased body weight have been re- 
ported in humans exposed to TCDD in the work place (16, 17, 
19). The TCDD induced anorexia may be due to a specific ef- 
fect on the regulatory systems of food intake. The regulation of 
food intake and appetite is an extremely complex process which 
involves numerous peptides and hormones (10,12). The hypo- 
thalamus has been considered to play a central role in this regu- 
lation (11). The hypothalamus maintains the nutritional homeostasis 
of the organism by activating or deactivating the food-seeking 
behaviors of the animal. It is known that endogenous opioid 
peptides (EOP) such as 13E play a physiological role in appetite 
and regulation of food intake (2, 6, 13). Different areas of the 
hypothalamus have been associated with EOP mediated modula- 
tion of eating. The hypothalamus, like the pituitary, contains 
proopiomelanocortin (POMC), the precursor molecule for the 
opioid 13E. 13E, a by-product of the precursor POMC peptide, is 
present in high concentrations in the hypothalamus (10). It has 
been suggested that decreased hypothalamic 13E concentration is 
a mechanism for the down regulation of feeding behavior to 
conserve energy during periodic food shortages (4). It has also 
been shown that opioid receptor receptor blockade (i.e., antago- 
nist binding) reduces food intake and body weight (2, 6, 13). 
The possibility exists that TCDD intoxication may affect levels 
of EOP and their receptors, which could have a profound im- 
pact on the regulation of feeding behavior. Thus this study was 
performed to assess if hypothalamic 13E and its brain receptor 
(mu) are associated with TCDD-induced anorexia and body 
weight decline. 
METHOD 
TCDD (50 p,g/kg) was administered in a single, oral dose to 
adult, male Sprague-Dawley rats (200--220g). This is a dose less 
than the reported LDso for adult, male Sprague-Dawley rats (60 
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p,g/kg) (1). However, it is important to note that in this strain of 
rats in our laboratory, a 50 ~g/kg oral dose of TCDD has never 
produced deaths at three weeks of exposure. Acetone-corn oil 
(1:2; 3.8 ml/kg), served as the control vehicle. Rats were per- 
mitted food and water ad lib. A weight-matched group of rats 
had their food restricted. At early time periods of 1-3 days, it is 
not practical to employ paired-feeding studies since they com- 
prise providing food amounts consumed the previous day. There- 
fore, food-restricted rats were given the amount of food consumed 
from previous experiments in which 30 rats of the same weight 
range were administered the same dose of TCDD (50 p,g/kg; 
single oral dose). These restricted amounts of food were 3, 6, 
and 6 grams at days 1, 2, and 3, respectively. This was done to 
confirm that the effects of treatment were due to TCDD and not 
to a decrease in food intake. All animals were maintained on a 
controlled light cycle (6:00 a.m. lights on; 6:00 p.m. lights off), 
with restricted access to minimize environmental disturbances to 
the rats for the duration of the experiment. Rats were killed 
(9:00 a.m.) by decapitation, their brains rapidly removed, and 
hypothalamic blocks dissected with the following limits: cuts 
were made posterior to the optic chiasm, anterior to the mamill- 
ary bodies and through the lateral hypothalamic sulci, with a 
depth of 2 mm. The hypothalami were frozen in liquid nitrogen, 
lyophilized and extracted in 0.1 N HC1 (15). Hypothalamic ex- 
tracts were analyzed for 13E content using a radioimmunoassay 
kit obtained from INCSTAR (Stillwater, MN). The sensitivity 
of the assay was 10 pg/ml. The data were statistically evaluated 
by analysis of variance 09<0.05) with differences between means 
evaluated by Tukey's Test (,o<0.05). 
Membranes from rat cerebrum were prepared and mu opioid 
receptor binding assays were performed (3). The binding-assay 
reaction consisted of 190 I~1 of membrane suspension (approxi- 
mately 0.6 mg/ml protein), 20 ixl of distilled H20, 25 Ixl of ei- 
ther distilled H20 or excess (2 v,M) [D-Ala 2, NMe-Pbe 4, Gly- 
ol]-Enkephalin (DAGO), and 25 Ixl of the appropriate concentration 
of SH-DAGO (0.125-10 nM) in 8 ml polypropylene tubes. The 
final volume of the assay was 260 I~l. Specific binding of the 
radioligand is defined as the difference between binding in the 
absence and presence of an appropriate excess of DAGO. After 
incubation for 80 minutes at 25°C (reflecting binding equilibri- 
um), the samples were filtered through glass fiber filters (GF/ 
C). The filtered samples were washed with ice cold 50 mM 
Tris-HC1, pH 7.4, and placed into polyethylene counting vials. 
After addition of 1 ml absolute ethanol followed by 10 ml of 
biodegradable scintillation fluid, vials were subjected to liquid 
scintillation counting. Receptor number (Bronx) and binding af- 
finity (Kd) were determined by Scatchard analysis (18). Protein 
concentration was determined by the method of Lowry and co- 
workers (8). The data were statistically evaluated by analysis of 
variance (p<0.05) with differences between means evaluated by 
Tukey's Test (p<0.05). 
RESULTS 
Body weights did not differ at days 1 and 2 for control, 
food-restricted control or TCDD groups. At day 3, body weights 
of TCDD-treated animals (196__ +  5) were significantly lower than 
control (223--.4) or food-restricted control (220+-.6) groups, 
which did not differ from each other. Rat hypothalamic 13E con- 
centrations were initially found to be significantly higher than 
controls at day 1, and then were significantly depressed at days 
2 and 3 following the administration of TCDD (Fig. 1). Hypo- 
thalamic I~E levels were increased to 166% of controls on day 
I; whereas at days 2 and 3 hypothalamic 13E concentrations were 
depressed to 39% and 49% of control values, respectively. Re- 
stricting the food intake did not change hypothalamic [3E con- 
t , 20G 
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FIG. 1. Rat hypothalamic [3E concentrations after exposure to TCDD. 
Rats received a single, oral dose of 50 izg/kg at day 0. Values represent 
the mean +_ SEM for four rats. [3E was measured by radioimmunoassay. 
Mean control values were 6.0 pg [3E,/hypothalamus_ + 1.5, 12.4__. 1.6 and 
11.6+-1.9 for days 1, 2 and 3, respectively. Mean [~E concentrations 
following three days of food restriction were 12.3 +- 1.7 pg IBE/hypothal- 
amus. Asterisks denote significant difference (p<0.05) between control 
and TCDD-treated rats. 
centration at day 3 (11.6+--1.9 and 12.3+__1.7 for control and 
food-restricted control groups, respectively: p>0.05). The recep- 
tor for 13E (mu) was then analyzed after TCDD treatment by 
Scatchard analysis. Brain mu receptor number (Bm~,) at day 3 
was increased 60% over control values following administration 
of TCDD, but the binding affinity (Ka) of the mu receptor re- 
mained unchanged. Restricting the food intake did not change 
either brain mu receptor number or affinity (Table 1). Figure 2 
shows a typical Scatchard plot of the specific binding of DAGO 
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FIG. 2. Scatchard transformation of [3H]DAGO binding to control and 
TCDD-treated rat membranes. A typical experiment is shown; data from 
several experiments are summarized in Table 1. The r value was greater 
than .940 in all cases. 
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TABLE 1 
EFFECT OF TCDD ON RAT BRAIN MU OPIOID RECEPTORS 
Bmax Kd 
Treatment (fmol/mg) (n_M) 
Control 53.3 ~ 7.3 0.40 +_ 0.08 
TCDD 85.6 -+ 3.5* 0.50 _+ 0.05 
Food Restricted 52.0 _ 5.3 0.43 _ 0.05 
Rats were treated with a single, oral dose of TCDD (50 p.g/kg) and 
sacrificed at day 3. 
Values represent the mean _+ SEM for 4 rats. 
*Denotes a significant difference (p<0.05) between control and 
treated rats. 
DISCUSSION 
It is known that EOP are involved in the highly complex 
chain of events forming the biochemical basis of appetite and 
regulation of food intake. It has been suggested that a decrease 
in hypothalamic 13E levels is a mechanism for the down regula- 
tion of feeding behavior to conserve energy during periodic food 
shortages (4). It has also been shown that opioid receptor antag- 
onists reduce food intake and body weight by displacement of 
opioid peptides at their binding site (2, 6, 13). A characteristic 
of antagonist treatment is an upregulation of the opioid receptor 
(14, 20--22). Since the present study shows that TCDD causes 
an increase in receptor number, it appears that TCDD may be 
acting as an opioid antagonist. This change, along with the de- 
crease in hypothalamic 13E levels, is coincident with the time 
interval that rats begin to exhibit reduced-food intake and pro- 
gressive weight loss after exposure to TCDD. In addition, rats 
receiving an amount of food comparable to that consumed by 
TCDD-treated rats had 13E and mu receptor numbers similar to 
control rats. These results demonstrate discrete effects of TCDD 
which axe not due to a decrease in food consumption. Thus our 
data suggest that a mechanism by which TCDD exerts its effects 
on rat appetite regulation is two fold; first, by decreasing hypo- 
thalamic I3E levels and second, by displacement of 13E at the 
opioid receptor site. These data do not rule out the possible par- 
ticipation of biogenic amines, other neuropeptides or hormones 
in TCDD-induced hypophagia. 
Conclusion 
The present findings suggest that EOP may contribute to the 
mechanisms by which TCDD exposure leads to depressed food 
intake and progressive weight loss. This knowledge may ulti- 
mately lead to information enabling treatment regimens to re- 
store feeding and correct body weight loss associated with exposure 
to this toxicant. 
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